Background/Aims: Cardiac fibrosis, characterized by an unbalanced production and degradation of extracellular matrix components, is a common pathophysiology of multiple cardiovascular diseases. Recent studies suggested that endothelial to mesenchymal transition (EndMT) could be a source of activated fibroblasts and contribute to cardiac fibrosis. Here, the role of pioglitazone (PIO) in cardiac fibrosis and EndMT was elaborated. Methods: Male C57BL/6 mice were subjected to aortic banding (AB), which was used to construct a model of pressure overload-induced cardiac hypertrophy. PIO and GW9662 was given for 4 weeks to detect the effects of PIO on EndMT. Results: Our results showed PIO treatment attenuated cardiac hypertrophy, dysfunction and fibrosis response to pressure overload. Mechanistically, PIO suppressed the TGF-β/Smad signaling pathway activated by 4-week AB surgery. Moreover, PIO dramatically inhibited EndMT in vivo and in vitro stimulated by pressure overload or TGF-β. A selective antagonist of PPAR-γ, GW9662, neutralized the anti-fibrotic effect and abolished the inhibitory effect of EndMT during the treatment of PIO. Conclusion: Our data implied that PIO exerts an alleviative effect on cardiac fibrosis via inhibition of the TGF-β/Smad signaling pathway and EndMT by activating PPAR-γ.
Introduction
Cardiac fibrosis is a hallmark of multiple cardiovascular diseases, including cardiac infarction, hypertension, dilated cardiomyopathy and diabetes [1] . Characterized by an unbalanced production and degradation of extracellular matrix components (ECM), cardiac fibrosis decreases myocardial wall compliance, causing impaired cardiac function and facilitating arrhythmogenesis [2] . Traditionally, proliferation of resident fibroblasts and migration of bone marrow-derived circulating fibrocytes is considered the major source of activated fibroblasts [3] . Recent studies have suggested that endothelial to mesenchymal transition (EndMT) could be another source of activated fibroblasts and contribute to cardiac fibrosis in mice [4] [5] [6] . In the progression of EndMT, endothelial cells decrease the expression of their specific markers, including CD31, VE-cadherin, and gain the characteristic phenotypes of fibroblasts such as α-smooth muscle actin (α-SMA) and vimentin. Finally, these cells transform to activated fibroblasts and migrate to the interstitial tissues, aggravating the cardiac fibrosis [7] . Thus, inhibition of EndMT is considered a potential therapy for cardiac fibrosis [8] .
Transforming growth factor-β (TGF-β)/Smad signaling pathway has been identified as one potential stimulus of EndMT in the progression of cardiac fibrosis [9] . Moreover, activation of peroxisome proliferator-activated receptor (PPAR)-γ could counteract the TGF-β/Smad effect. PPAR-γ, as one nuclear orphan receptor, has been implicated in regulating a variety of biological processes within the cardiovascular system, including cardiac hypertrophic, fibrotic and inflammatory responses to hemodynamic stress [10, 11] . Pioglitazone (PIO), as a classic PPAR-γ receptor agonist, has been shown to alleviate cardiac hypertrophy induced by pressure overload in mice [12] . Moreover, a previous study indicated that PIO repressed the synthesis of type III collagen and myocardial fibrosis in type 2 diabetic patient s [13] . However, the anti-fibrotic mechanism of pioglitazone is still elusive.
Based on the previous finding, we assume that pioglitazone may reduce cardiac fibrosis induced by pressure overload via inhibition of EndMT. In the present study, we aimed to investigate the effect of PIO on EndMT in cardiac fibrosis.
Materials and Methods
Reagents PIO and GW9662 (LTD >98%) were purchased from Sigma-Aldrich. Recombinant human TGF-β1 protein (ab50036) was purchased from Abcam. Antibodies against the following proteins were purchased from Abcam: TGF-β1 (ab64715), vimentin (ab92547), α-SMA (ab5694), and CD31(ab24590). The following antibodies were purchased from Cell Signaling Technology: phospho-(P-)smad2 (3101), total-(T-)smad2 (3103s), P-smad3 (8769), T-smad3 (39513s), and GAPDH (2118). The antibodies against PPAR-γ (sc-7196) were purchased from Santa Cruz Biotechnology. All the secondary antibodies used in the research were obtained from LI-COR Biosciences. The BCA protein assay kit obtained from Pierce (Rockford, IL, USA).
Animals and treatment
All animal experiments were approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Male C57BL/6 mice of 8-10 weeks of age (23.5-27.5 g) purchased from the Institute of Laboratory Animal Science, CAMS & PUMC (Beijing, China) were used in the experiments. All the mice were randomly assigned to the SHAM or aortic banding (AB) groups. The cardiac hypertrophy model of mouse was established by AB-induced pressure overload and performed according to previously described methods [14] . PIO (2.5 mg/kg/day) was given orally for 4 weeks, which was begun after 1 week of AB. Meanwhile, GW9662 was injected intraperitoneally for 4 weeks in a dose of 1 mg/kg every other day. The control mice received saline infusion solely. The doses of the PIO [10] and GW9662 [15] were administered according to the previous literature. At the end of 4 weeks, the animals were sacrificed by injecting excessive sodium pentobarbital after echocardiography analysis. Subsequently, hearts were removed and weighed for computing the heart weight/body weight (HW/BW) ratios.
Echocardiographic and hemodynamic analysis
To evaluate the cardiac function, echocardiography was performed using a 10-MHz linear array ultrasound transducer equipped with a Mylab 30CV (Esaote S.P.A, Italy) ultrasound system [16, 17] . In brief, the mice were anaesthetized with continuous 1.5-2% isoflurane inhalation. The function of left ventricle Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry (LV) was detected at the level of the mid-papillary muscles. The heart rate (HR) and LV ejection fraction (LVEF) were measured. For hemodynamic detection, mice were anesthetized with 2% isoflurane, and then an incision was made in the right carotid; a 1.4-F Millar micro-tip pressure transducer (Millar, Houston, USA) was inserted and advanced into the left ventricle. The heart rates, pressure and dp/dt values were recorded continuously via a pressure-volume conductance system (Millar, Houston, USA) after stabilization for 15 minutes. The hemodynamic parameters, including end-systolic pressure (ESP), end-systolic volume (ESV), end-diastolic volume (EDV), the maximal rate of pressure development (dp/dt max) and minimal rate of pressure decay (dp/dt min), were analyzed using Chart 5.0 software.
Histological analysis
Five weeks after the sham or AB surgery, the hearts of the mice were excised and arrested in the diastolic stage with a 10% KCL solution. Then, the fixed hearts with 10% formalin were embedded in paraffin according to standard histological protocols. For histopathology staining, embedded hearts were cut transversely into 5-μm sections. To evaluate the cardiomyocytes hypertrophy and collagen deposition, the sections of heart mounted onto slides were stained with hematoxylin-eosin (H&E) and picrosirius red (PSR), respectively. Fluorescein isothiocyanate-conjugated wheat germ agglutinin (WGA) staining was administered to detect the myocyte cross-sectional areas, and the nuclei were stained by 4, 6-diamidino-2-phenylindole (DAPI). The cell cross-sectional areas and collagen deposition were analyzed by Image-Pro Plus software (version 6.0) with captured images. At least 100 left ventricular myocytes and 40 fields per group were calculated.
Cell culture and treatments
The human umbilical vein endothelial cell (HUVEC)-12 cell line used for the in vitro studies were purchased from YRGene (NC006). All cells used in our study were cultured in a humidified atmosphere of 5% CO2 at 37 °C. The HUVECs were seeded into 6-or 24-well culture plates and cultivated using Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. After 48 hours, the medium cultured cells were exchanged with serum-free DMEM for 8 hours. Later, the HUVECs were stimulated with recombinant human TGF-β1 (ABCAM, ab50036, 10 ng/ml) or PBS for another 24 hours. Meanwhile, PIO (20 μM) and GW9662 (20 μM) were given to detect the effects of PIO on EndMT.
Immunohistochemistry and immunofluorescence staining
For immunohistochemistry and immunohistochemistry staining, the paraffin slices of mice cardiac tissues were processed with high-pressure antigen retrieval process in citrate buffer (PH=6.0). Afterwards, the slices were blocked with 8% goat serum albumin for 1 hour and incubated with the primary antibodies overnight at 4°C. Then, the appropriate peroxidase-conjugated or fluorescent secondary antibody were incubated for 1 hour at 37°C.
For immunohistochemistry staining of HUVECs, the cell coverslips were fixed with 4% formaldehyde and permeabilized with 0.2% Triton X-100 in PBS. Subsequently, the HUVECs in coverslips were blocked with 8% goat serum albumin, incubated with appropriate primary antibodies, which was followed by staining with fluorescent secondary antibody. Images of slides were detected using Nikon light microscopy (H550L, Tokyo, Japan) or fluorescence microscopy (BX51, Olympus, Japan).
Western blot analysis
Cardiac tissue or HUVEC samples were homogenized in lysis buffer. The BCA Protein Assay Kit was used to measure the concentration of the protein samples. Equal amounts of protein were fractionated by SDS 10% polyacrylamide gels and transferred to PVDF membranes. After being incubated with the primary antibodies at 4°C overnight, the membranes then incubated with secondary antibody for 60 min. Blots were visualized and analyzed using an Odyssey Infrared Imaging System (LI-COR Biosciences, USA) and normalized to GAPDH.
Real-time reverse transcriptase polymerase chain reaction
For total RNA extraction, heart tissues and HUVECs were thawed in TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and first strand cDNA was synthesized using oligo (dT) primers and a cDNA synthesis kit (Roche, Mannheim, Germany). Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry performed using a LightCycler 480 SYBR Green Master Mix (Roche, Mannheim, Germany). The primer details in the study are shown in Table 1 . The mRNA expression levels were normalized to GAPDH gene expression.
Statistical analysis
All values are presented as the mean ± SEM. Statistical significance was assessed by one-way analysis of variance followed by Tukey's post hoc test using SPSS 19.0 software. P<0.05 were considered to be statistically significant.
Results

PIO alleviated cardiac hypertrophy and ameliorated cardiac function under pressure overload
Consistent with our previous study [12] , the expression of PPAR-γ was decreased after long-term pressure overload (Fig. 1A) . To evaluate the protective role of PIO in cardiac hypertrophy, we constructed a mouse model of cardiac hypertrophy induced by pressure overload and treated with PIO or saline orally for 4 weeks. Consistent with our previous study [10] , the mice subjected to AB surgery displayed significantly increased HW/BW ratios (Fig. 1B) compared with sham control as well as an enlarged myocytes area (Fig. 1C-D) . In parallel, echocardiographic and hemodynamic analyses also revealed better systolic and diastolic left ventricle function in the AB+PIO group compared with mice in AB+Veh, as evaluated by ESP, dp/dt max, dp/dt min and LVEF (Table 2) . Collectively, these re- To evaluate the role of PIO in cardiac fibrosis, mouse hearts subjected to AB surgery exhibited more prominently increased fibrosis in interstitial and perivascular areas compared with mice in the SHAM group ( Fig.  2A) . Furthermore, treatment with PIO significantly attenuated the fibrosis induced by pressure overload. Consistently, PIO reduced the elevated mRNA levels of markers involved in cardiac fibrosis, including fibronectin, collagen I, and collagen III (Fig. 2C) .
The TGF-β/Smad pathway has been shown to be closely implicated in cardiac fibrosis. Moreover, PPAR-γ activation exerted antifibrotic effects via the modulation of TGF-β-mediated pathways [18] . Our study has found that the protein expression of TGF-β, P-smad2 and Psmad3 was upregulated in the cardiac tissues following pressure overload stimulation, and PIO supplementation markedly decreased the above protein expression (Fig. 2D) . No difference was observed in SHAM groups with or without PIO treatment. Immunohistochemistry staining and RT-PCR analysis were further performed to evaluate the expression of TGF-β in cardiac tissue. Consistent with the inhibition effect of TGF-β expression, PIO resulted in the reduced staining intensity and mRNA expression of TGF-β in cardiac tissues (Fig. 2B) . We also detected that PIO markedly elevated Table 2 . Echocardiographic and hemodynamic parameters in mice after 4 weeks of aortic binding. HR= heart rate; ESP= end-systolic pressure; ESV= end-systolic volume; EDV= end-diastolic volume; dp/ dt min= minimal rate of pressure decay; dp/dt max= maximal rate of pressure development; LVEF= left ventricular ejection fraction. 
PIO attenuated endothelial to mesenchymal transition
EndMT could be one source of activated fibroblasts and contribute to cardiac fibrosis induced by pressure overload [4] . To gain further insight into the role of PIO in the progress of EndMT, we detected mRNA expression levels of snail1, snail2 and twist1 by RT-PCR. As critical mesenchymal cell transcriptional regulators, the expression of snail1, snail2 and twist1 was significantly increased in heart tissues following AB surgery compared with the SHAM group. Administration of PIO markedly reduced the increased mRNA expression of mesenchymal cell transcriptional regulator induced by pressure overload (Fig. 3A) . There was no significant difference between the SHAM+Vehicle and SHAM+PIO groups. Furthermore, Western blot results indicated that pressure overload induced EndMT in the heart, which presented as the reduced expression of endothelial marker CD31 and the enhanced expression of the mesenchymal markers, including α-SMA and vimentin (Fig. 3B) . Immunofluorescence staining of CD31 and α-SMA ulteriorly showed PIO suppresses the development and progression of EndMT (Fig. 3C) . These data suggested that PIO attenuates cardiac fibrosis via inhibition of EndMT in hearts.
PIO suppressed cardiac fibrosis and EndMT by activation of PPAR-γ
Next, we explored whether PIO exerts alleviative role in cardiac fibrosis and EndMT induced by pressure overload via activation of PPAR-γ. Treatment with GW9662, a selective PPAR-γ antagonist, abolished the anti-fibrotic effect of PIO in the hypertrophic heart, as indicated by the increased LV collagen deposition in interstitial and perivascular region (Fig.  4A ) and up-regulated mRNA expression of collagen I and collagen III (Fig. 4B) . Moreover, the expression of TGF-β was down-regulated in the hypertrophic heart following PIO treatment, which was also abolished by GW9662 (Fig. 4C) . To further examine PIO involvement in regulating the EndMT, GW9662 was administered to inhibit the activity of PPAR-γ. As shown in Fig. 4D , the inhibitory effects of PIO on EndMT was abrogated by GW9662, as evidenced by 
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PIO inhibited the transition of HUVECs stimulated by TGF-β
After verifying the protective effect of PIO in EndMT in vivo, we further evaluated the inhibitory effects of PIO on EndMT using cultured HUVECs in vitro. After TGF-β stimulation for 24 hours, we observed an increased endothelial to mesenchymal transition, which indicated as the increased expression of α-SMA and vimentin, as well as the reduced expression of CD31 (Fig. 5A) . Treatment of PIO reversed the expression changes of the above proteins, and GW9662 dramatically abolished the inhibition of EndMT by PIO, as indicated by the elevated mRNA expression of snail1 and snail2 (Fig. 5B) . Immunofluorescence staining of CD31 and vimentin in HUVECs showed PIO inhibited the loss of endothelial marker CD31 and gain of mesenchymal marker vimentin (Fig. 5C) . Likewise, the alleviative effect of EndMT by PIO was dramatically blocked by the treatment with GW9662. These data indicated that the protection of PIO against EndMT was abolished by GW9662 in vitro, owing to the inhibition of PPAR-γ.
Discussion
Cardiac fibrosis is a significant global health problem associated with different forms of cardiovascular diseases. Cardiac fibrosis not only resulted in cardiac diastolic dysfunction but also increased the risk of arrhythmia, heart failure and sudden cardiac death. Recent studies have shown that endothelial cells, in addition to resident fibroblasts and bone marrowderived fibroblasts, contribute to the development of various organic fibrosis in an EndMT way [4, 19] . In our previous study, we have demonstrated that administration of PIO protects against cardiac remodeling following pressure overload in mice. To elucidate anti-fibrotic mechanism of PIO, our results indicated that (1) PIO treatment attenuates cardiac fibrosis and suppresses the TGF-β/Smad signaling pathway activated by pressure overload; (2) PIO dramatically mitigated EndMT in vivo and in vitro when stimulated by pressure overload or TGF-β in HUVECs; and (3) GW9662, a selective antagonist of PPAR-γ, neutralized the antifibrotic effect and abolished the inhibitory effect of EndMT during the treatment of PIO. Our data suggested that PIO exerts the alleviative effect on cardiac fibrosis via inhibition of the TGF-β/Smad signaling pathway and EndMT by activating PPAR-γ.
PPAR-γ, as a ligand-activated nuclear receptor, has been illustrated for a wide range of pharmacological actions [20] . In addition to its known role in enhancing insulin sensitivity, PPAR-γ has been implicated in mediating both inflammation and fibrosis in heart and lungs. Activation of PPAR-γ by administration of atorvastatin retarded advanced glycation end products (AGEs) and induced fibroblast proliferation and differentiation [21] . Rosiglitazone, a PPAR-γ ligand, prevented the increased expression of α-SMA and fibrillar collagen synthesis stimulated by TGF-β1 in cultured lung fibroblasts [22] and attenuated cardiac fibrosis in pressure-overload induced hypertension in rats [23] . In addition, cardiac-specific PPAR-γ-knockout mice presented spontaneous cardiac hypertrophy with preserved systolic cardiac function [24] . Furthermore, extensive evidence has demonstrated that there is a functional interaction between TGF-β and endogenous PPAR-γ expression in pressure overloaded heart in vivo and isolated cardiac fibroblasts in vitro [25] . Additionally, previous studies implied that PPAR-γ is intimately associated with the regulation of TGF-β signaling pathway. In our present study, PIO supplementation alleviated cardiac fibrosis and suppressed the TGF-β/ Smad signaling pathway induced by pressure overload, as indicated by decreased protein expression of TGF-β, P-smad2 and P-smad3. However, as a PPAR-γ ligand, the effect of PIO on EndMT and in the progression of cardiac fibrosis induced by pressure overload are still unknown.
Emerging evidence has emphasized momentous effects for EndMT on the development and progression of fibrosis in various organs, such as lung, kidney and heart. Hashimoto et [4] . Afterwards, they adopted endothelial lineage tracing and observed the emergence of fibroblasts derived from EndMT in the process of kidney fibrosis s [27] . Interestingly, extensive research has attested that TGF-β signaling is potentially involved in the stimulation of EndMT [4, 9, 28] . Xavier et al. utilized heterozygous endothelium-specific TGF-β receptor knockout mice and supported that ablating TGF-β signaling is sufficient to curtail EndMT and thereby attenuate the fibrotic responses in injured kidney [29] . In the progression of cardiac fibrosis, the Smad3-dependent TGF-β signaling pathway was implicated in initiation of EndMT [30] . In Smad3 heterozygous mice, cardiac fibrosis was markedly attenuated and associated with a decrease in the number of endothelial-derived fibroblasts [31] . Consistent with these findings, activated TGF-β/Smad signaling and emerged EndMT were also observed in a pressure overload mouse model induced by 4-week AB surgery in our present study, and activation of PPAR-γ inhibited the development of EndMT via PIO treatment. In our in vitro study, EndMT is able to be induced by stimulation of TGF-β [30] . Our present study has indicated TGF-β1-induced EndMT in HUVECs enhanced the mRNA expression of mesenchymal markers, such as vimentin and decreased the expression of endothelial marker CD31. Meanwhile, we also observed the inhibitory effect of PIO on TGF-β-induced EndMT in HUVECs. Additionally, GW9662, a selective antagonist of PPAR-γ, abolished the inhibitory effect of EndMT during the treatment of PIO.
Conclusion
With EndMT contributing to the total pool of cardiac fibroblasts and TGF-β as a pivotal mediator of this response, this provides opportunities to alleviate fibrosis by targeting TGF-β. Importantly, activation of PPAR-γ significantly suppressed the TGF-β/Smad signaling pathway in the progression of cardiac remodeling [32] . Our study provides the scientific data that activation of PPAR-γ is implicated in the anti-fibrotic effect of PIO on pressure overloaded hearts in vivo and TGF-β-induced EndMT in HUVECs. These results may potentially extend our understanding of the mechanisms of cardioprotective effects of PIO and support the notion that retardation of EndMT by administration of PIO contributes to the alleviation of cardiac fibrosis induced by pressure overload. However, further investigation in different animal models is under way.
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